Merck & Co. Inc. stock underperforms Friday when compared to competitors
Shares of Merck & Co. Inc. MRK sank 0.60% to $99.25 Friday, on what proved to be an all-around rough trading session for the ...
Merck downgraded by Truist to hold over growth concerns
Truist has downgraded Merck (NYSE:MRK) to hold from buy, citing upcoming loss of market exclusivity and continuing headwinds ...
Merck says HPV vaccine for men approved by China's drug regulator
U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's ...
Merck & Co. Inc. stock outperforms competitors despite losses on the day
The stock's fall snapped a two-day winning streak.
WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million
WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...
BioSpace8h
Pfizer’s Subcutaneous PD-1 Blocker Aces Phase III in Bladder Cancer, Carves Niche Versus Keytruda
If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...
Merck downgraded to Hold from Buy at Truist
Truist downgraded Merck (MRK) to Hold from Buy with a price target of $110, down from $130, as part of a broader research note previewing FY25 ...
WuXi Bio to Sell Vaccine Facility to Merck for $500 Million
WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...
Atropos Health Collaborates with Merck for Rapid Evidence Generation to Accelerate Innovation for Life-Saving Treatments
Atropos Health, a pioneer in translating real-world clinical data into real-world evidence (RWE) for decision-making, today ...
Mirror Biologics Enters Clinical Collaboration with Merck KGaA, Darmstadt, Germany in Metastatic Colorectal Cancer
Colorectal cancer (CRC) is the third most common cancer and the second most common cause of cancer deaths worldwide. In 2023, ...